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Objective. The aim of this study was to investigate regenerative eﬀects of ultrasound- (US-) guided injection with human umbilical
cord blood-derived mesenchymal stem cells (UCB-MSCs) and/or polydeoxyribonucleotide (PDRN) injection in a chronic
traumatic full-thickness rotator cuﬀ tendon tear (FTRCTT) in a rabbit model. Methods. Rabbits (n = 32) were allocated into 4
groups. After a 5mm sized FTRCTT just proximal to the insertion site on the subscapularis tendon was created by excision, the
wound was immediately covered by a silicone tube to prevent natural healing. After 6 weeks, 4 injectants (0.2mL normal saline,
G1-SAL; 0.2mL PDRN, G2-PDRN; 0.2mL UCB-MSCs, G3-MSC; and 0.2mL UCB-MSCs with 0.2ml PDRN, G4-MSC
+PDRN) were injected into the FTRCTT under US guidance. We evaluated gross morphologic changes on all rabbits after
sacriﬁce. Masson’s trichrome, anti-type 1 collagen antibody, bromodeoxyuridine, proliferating cell nuclear antigen, vascular
endothelial growth factor, and platelet endothelial cell adhesion molecule stain were performed to evaluate histological changes.
Motion analysis was also performed. Results. The gross morphologic mean tendon tear size in G3-MSC and G4-MSC+PDRN
was signiﬁcantly smaller than that in G1-SAL and G2-PDRN (p < 0 05). However, there were no signiﬁcant diﬀerences in the
tendon tear size between G3-MSC and G4-MSC+PDRN. In G4-MSC+PDRN, newly regenerated collagen type 1 ﬁbers,
proliferating cell activity, angiogenesis, walking distance, fast walking time, and mean walking speed were greater than those
in the other three groups on histological examination and motion analysis. Conclusions. Coinjection of UCB-MSCs and
PDRN was more eﬀective than UCB-MSC injection alone in histological and motion analysis in a rabbit model of chronic
traumatic FTRCTT. However, there was no signiﬁcant diﬀerence in gross morphologic change of tendon tear between UCB-
MSCs with/without PDRN injection. The results of this study regarding the combination of UCB-MSCs and PDRN are worth
additional investigations.
1. Introduction
Rotator cuﬀ tendon tears (RCTTs) are the most common
tendon injury in adults and aﬀect about 30% of people over
60 years of age [1]. Although surgical repair of a RCTT is
one of the most common orthopedic procedures, the failure
rate for rotator cuﬀ tendon repair ranges widely from 20%
to 90% [2]. The current therapeutic approaches do not
achieve physiological restoration of the RCTT, and the qual-
ity of the repaired tendon is not optimal [3]. These deﬁcien-
cies have driven attempts to regenerate RCTT with the use of
biological adjuvants. Mesenchymal stem cells (MSCs) have
been proposed as an attractive alternative to overcome the
limitations of the current treatments [4]. Of the various
MSCs, human umbilical cord blood-derived MSCs (UCB-
MSC) have a greater therapeutic potential than MSCs
derived from other tissues because of attributes that include
the ability to home in on injured tissue, low immunogenicity,
multidirectional diﬀerentiation, and extensive secretion pro-
ﬁles [5]. The function of autologous MSCs in patients with
advanced age or signiﬁcant comorbidities is impaired, and
allogeneic UCB-MSCs may therefore be of particular beneﬁt
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in the elderly or those with multiple comorbidities [6]. In
addition, UCB-MSCs can be produced commercially in
larger quantities with the same quality.
Polydeoxyribonucleotide (PDRN) is a biological adjuvant
which has the same advantages as UCB-MSCs in terms of
commercial mass production. PDRN is a mixture of DNA
polymers featuring a chain with length ranging from 50 to
2000 bp. It is extracted from the trout sperm and puriﬁed as
a preparation containing a high percentage of DNA. PDRN
is a source of pyrimidines and purines and stimulates nucleic
acid synthesis through the salvage pathway [7]. PDRN can
induce angiogenesis and collagen synthesis and also has an
anti-inﬂammatory activity [8]. One recently published study
reported the eﬀectiveness of PDRN in the treatment of
chronic rotator cuﬀ disease [9].
The aim of our study was to evaluate the eﬃcacy of UCB-
MSCs and/or PDRN injections in regenerating RCT in a rab-
bit model. This is the ﬁrst report to compare the regenerative
eﬀects of stem cell and PDRN in a model of RCTT.
2. Material and Methods
2.1. Animal Model. Twelve-week-old, male, New Zealand
white rabbits (n = 32) were housed in separate metal cages
at a temperature of 23± 2°C and a relative humidity of 45±
10%. They had free access to tap water and were fed a com-
mercial rabbit diet. None of the rabbits received additional
exercise, and all were allowed to do normal activities in a
65× 45× 30 cm cage. Animal experiments were performed
in accordance with internationally accredited guidelines
and approved by the University of School of Medicine
Animal Care and Use Committee.
Anesthesia was induced using isoﬂurane (JW Pharma-
ceutical, Goyang, South Korea) vaporized in oxygen and
delivered using a large animal cycling system. Under general
anesthesia, 5mm diameter full-thickness RCTTs (FTRCTTs)
were created just proximal to the insertion site on the left
subscapularis tendon by punch biopsy excision using a
Biopsy Punch 5mm LZ (SFM, Wächtersbach, Germany).
Each excision wound was immediately covered with a resorb-
able round silicone Penrose drainage tube (Sewoon Medical
Co. Ltd., Cheonan, South Korea) to induce a chronic rotator
cuﬀ tear. The incision was closed using subcutaneous and
skin sutures [10].
2.2. Mesenchymal Stem Cells. UCB was collected from the
umbilical veins of pregnant women after neonatal delivery
with informed consent. MSCs were isolated from the UCB
and cultivated [11, 12]. The cells expressed cluster of diﬀer-
entiation 105 (CD105, 96.93%), CD90 (98.96%), CD29
(98.26%), CD166 (81.29%), CD73 (83.49%), CD45 (0.26%),
CD14 (1.0%), and human leukocyte antigen D related
(HLA-DR, 0.18%). They also expressed pluripotent markers
including octamer-binding transcription factor 4 (30.5%)
and stage-speciﬁc embryonic antigen 4 (67.7%). UCB-
MSCs can diﬀerentiate into cell types including respiratory
epithelium, osteoblasts, chondrocytes, and adipocytes with
speciﬁc in vitro induction stimuli [13–15]. We conﬁrmed
the diﬀerentiation potential and karyotypic stability of the
UCB-MSCs up to passage 11. UCB-MSCs were mixed with
viscous hyaluronic acid.
2.3. Animal Grouping and Injection. Six weeks after the exci-
sions, the inserted tubes were removed to induce chronic
FTRCTT. The site of each full-thickness subscapularis ten-
don tear was conﬁrmed, and the incision was using subcu-
taneous and skin sutures. Rabbits were randomly allocated
into four treatment groups (n = 8 per group) 6 weeks after
excision. Group 1 (G1-SAL) was injected with 0.2mL of
normal saline, group 2 (G2-PDRN) with 0.2mL commer-
cially obtained PDRN (Hidr, BMI Korea, Seoul, Korea;
Figure 1(a)), group 3 (G3-MSC) with 0.2mL (1× 106 cells)
UCB-MSCs (Figures 1(b)–1(d)), and group 4 (G4-MSC+
PDRN) with 0.2mL UCB-MSCs and 0.2mL PDRN. All
rabbits were euthanized 4 weeks postinjection (Figure 2).
All injections were performed under ultrasound (US) guid-
ance using an US system with an 18~5MHz multifrequency
linear transducer (EPIQ 5; Philips Healthcare, Andover,
MA, USA). No medication was administered, and all rabbits
were immobilized in the equinus position using an elastic
bandage for 2 days after the injection.
2.4. Gross Morphology Examination. Gross morphologic
examinations were conducted after each rabbit was eutha-
nized. Each tendon tear was classiﬁed as partial or full thick-
ness. Gross morphologic tendon tears were photographed to
the subscapularis tendon tear using a clear plastic ruler near
the center of the tear site to permit calculation of size using
ImageJ software (National Institute of Health, Bethesda,
MD) by tracing the outlined tear edge preinjection and
at 4 weeks postinjection.
2.5. Histological Examination Tissue Preparation. The rabbits
were sacriﬁced under general anesthesia after all intramuscu-
lar injections. The tear area of the subscapularis tendon was
segmented and ﬁxed with neutral-buﬀered formalin for 24
hours. Each specimen was embedded in paraﬃn (Paraplast;
Oxford, St. Louis, MO, USA) and sliced sagittally into 5μm
thick serial sections. The specimens were stained with
hematoxylin-eosin (H-E) and Masson’s Trichrome (MT)
stains and examined by light microscopy.
2.6. Immunohistochemistry. Immunohistochemical staining
of tendon sections was done for collagen ﬁbers using mouse
anti-collagen 1 monoclonal antibody (COL-1, Abcam,
Cambridge, UK) and for the marker of proliferating cells
using 5-bromo-2′-deoxyuridine (BrdU; Cayman Chemical,
Ann Arbor, MI, USA). To accomplish BrdU staining, rabbits
were postoperatively given 25mg/kg BrdU intraperitoneally.
Twenty-four hours later, each rabbit was sacriﬁced and
paraﬃn-embedded sections were prepared. The sections
were incubated in 0.1% trypsin for 10 minutes at 37°C and
1NHCl for 30 minutes at 56°C to denature the DNA. Endog-
enous peroxidases were inhibited by preincubation in 0.3%
hydrogen peroxide (H2O2) in phosphate-buﬀered saline
(PBS) for 30 minutes, and nonspeciﬁc protein binding was
blocked in PBS containing 10% normal horse serum (Vector
Laboratories, Burlingame, CA, USA) for 30 minutes. The sec-
tions were incubated in monoclonal anti-BrdU (1 : 100,
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Sigma-Aldrich, St. Louis, MO, USA) for 2 hours at room
temperature and washed three times with PBS. The second-
ary antibody (1 : 100), biotinylated anti-mouse IgG (Vector
Laboratories), was placed on the sections for 1 hour at room
temperature, followed by three washes with PBS. Avidin-
biotin-peroxidase complex (ABC, Vector Laboratories) was
placed on the sections for 1 hour, followed by three PBS
washes, and further followed by a peroxidase reaction using
(a) (b)
T
(c)
I
(d)
Figure 1: Human umbilical cord blood-derived mesenchymal stem cells (MSCs), polydeoxyribonucleotide (PDRN), and ultrasound images.
(a) PDRN. (b) MSCs. (c) Injection was made in the left shoulder subscapularis full-thickness tears under ultrasound guidance. (d)
Longitudinal ultrasound image shows the needle (arrow) in the left shoulder subscapularis of the rabbit. T: tendon; I: injectant.
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Figure 2: Timeline of saline, PDRN, MSC, and PDRN with MSC injection. Normal saline (0.2mL; group 1: SAL), PDRN (0.2mL; group 2:
PDRN), MSC (0.2mL; group 3: MSC), and MSCs with PDRN (both 0.2mL; group 4: MSC+PDRN) were injected under ultrasound guidance
into the left shoulder subscapularis full-thickness tears 6 weeks after the tears were created. The analysis including gross morphology of tear
site, histologic examination, and motion analysis was performed 4 weeks after injection of four diﬀerent solutions. All rabbits were euthanized
by carbon monoxide inhalation 4 weeks after injection of the diﬀerent solutions. PDRN: polydeoxyribonucleotide; MSC: human umbilical
cord blood-derived mesenchymal stem cell.
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0.05M Tris-HCl (pH7.6) containing 0.01% H2O2 and 0.05%
3,3′-diaminobenzidine (Sigma-Aldrich). The sections were
counterstained with hematoxylin and then mounted. The
slides were examined with Axiophot Photomicroscope (Carl
Zeiss, Germany) and AxioCamMRc5 (Carl Zeiss, Germany).
The number of immunopositive cells or nuclei was counted.
The tendon sections were stained for the marker of pro-
liferating cells using mouse anti-proliferating cell nuclear
antigen monoclonal antibody (PCNA, PC10, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), angiogenic markers
using anti-vascular endothelial cell growth factor polyclonal
antibody (VEGF, A-20, Santa Cruz Biotechnology), and
anti-platelet endothelial cell adhesion molecule-1 polyclonal
antibody (PECAM-1, M-20, Santa Cruz Biotechnology).
Sections were immunostained for the marker of type I and
type III collagen ﬁbers using either mouse COL-I or mouse
COL III. The paraﬃn-embedded sections were cleared,
dehydrated, and washed with PBS. Antigen retrieval was
performed using ethylenediaminetetraacetic acid (EDTA)
buﬀer (1mM EDTA, pH8.0) for 30 minutes at 95°C followed
by cooling. Endogenous peroxidases were inhibited by prein-
cubation in 0.3% H2O2 in PBS for 30 minutes, and nonspe-
ciﬁc protein binding was blocked in PBS containing 10%
normal horse serum for 30 minutes. The sections were incu-
bated in primary antibodies (1 : 100~ 1 : 200) for 2 hours at
room temperature and washed three times with PBS. The
secondary antibody (1 : 100), biotinylated anti-mouse IgG
or biotinylated anti-rabbit IgG or biotinylated anti-goat IgG
(Vector Laboratories), was placed on the sections for 1 hour
at room temperature and washed three times with PBS.
Sections were exposed to ABC for 1 hour, washed three
times with PBS, and subjected to a peroxidase reaction
using 0.05M Tris-HCl (pH7.6) containing 0.01% H2O2 and
0.05% 3,3′-diaminobenzidine (DAB, Sigma-Aldrich). The
sections were counterstained with hematoxylin and then
mounted. The slides were examined using an Axiophot
Photomicroscope equipped with an AxioCam MRc5. Each
slide was evaluated according to the intensity of positive
immunostaining.
Thirty randomly selected ﬁelds from each group were
photographed using the AxioCam MRc5 interfaced with
the Axiophot Photomicroscope. The AxioVision SE64 (Carl
Zeiss, Germany) program was used for analysis. A semiquan-
titative scoring system for the nuclear BrdU, PCNA, and
cytoplasmic markers (VEGF, and PECAM-1) was used
considering the staining intensity and extent of the area;
this approach is widely accepted and has been used in pre-
vious studies [16, 17]. Brieﬂy, the proportion of positive
stained cells was scored as 0 (no cells stained positive), 1
(1%–10% stain-positive cells), 2 (11%–33% stain-positive
cells), 3 (34%–66% stain-positive cells), and 4 (67%–100%
stain-positive cells). The intensity of COL I or COL III
positive immunostaining was graded as −, +, ++, and +++
(negative, slight positive, moderate positive, and strong pos-
itive staining, resp.).
2.7. Motion Analysis. The motion analysis of the rabbits was
conducted at preinjection and 4 weeks postinjection. Rabbits
were habituated for 30 minutes to the open ﬁeld before
motion analysis was performed [18]. They were placed on a
3× 3M arena and allowed to freely explore the ﬁeld for 5
minutes. Their movements were individually assessed using
a video-tracking system equipped with a camera (Smart;
Panlab, Barcelona, Spain) that recorded the rabbit’s horizon-
tal activity. Five-minute walking distance, fast walking time,
and mean walking speed were measured.
2.8. Statistical Analysis. Statistical analyses were performed
with the SPSS program for Windows program, version 19.0
(SPSS Inc., Chicago, IL, USA). In addition to standard
descriptive statistical calculations (means and standard
errors), ANOVA was used to determine statistical diﬀerences
among intragroup and intergroup. When ANOVA yielded
signiﬁcant results indicating that the group was signiﬁcantly
diﬀerent from the others, Tukey’s test was also performed.
The mean values were followed by 95% conﬁdence intervals,
and all the data are expressed as the means± standard error.
The statistically signiﬁcant levels were predetermined at
P < 0 05 and P < 0 001.
3. Results
At 4 weeks postinjection, RCTT was observed in all eight rab-
bits in G1-SAL. In G2-PDRN, a partial-thickness subscapu-
laris tendon tear was observed in three rabbits (37.5%) and
full-thickness tendon tear in ﬁve rabbits (62.5%). In G3-
MSC, a partial-thickness subscapularis tendon tear was
observed in three rabbits (37.5%), full-thickness tendon tear
in two rabbits (25%), and nearly complete healing in three
rabbits (37.5%). In G4-MSC+PDRN, a partial-thickness
subscapularis tendon tear was observed in ﬁve rabbits
(62.5%), full-thickness tendon tear in one rabbit (12.5%),
and nearly complete healing in two rabbits (25%) (Figures 3
and 4). There were signiﬁcant diﬀerences in gross morpho-
logic changes between preinjection and four weeks postinjec-
tion in G3-MSC and G4-MSC+PDRN.
The gross morphologic mean tendon tear size of
each group at 4 weeks postinjection was 13.08mm2 (G1-
SAL), 13.27mm2 (G2-PDRN), 3.36mm2 (G3-MSC), and
3.35mm2 (G4-MSC+PDRN). The size of the tear in G3-
MSC and G4-MSC+PDRN was signiﬁcantly smaller than
that in G1-SAL and G2-PDRN (P < 0 05). There were no
signiﬁcant diﬀerences in gross morphologic changes and
tendon tear size between G3-MSC and G4-MSC+PDRN
(Figures 3 and 5).
On H-E staining, a parallel arrangement of hypercellular
ﬁbroblastic bundles was observed in G1-SAL, G2-PDRN, and
G3-MSC. This arrangement was hardly observed in G1-SAL.
On MT staining, regenerated collagen ﬁbers were observed
and were stained with COL-1 in G2-PDRN, G3-MSC,
and G4-MSC+PDRN, but staining was rare in G1-SAL
(Figure 6A1–B4). Numerous PCNA and BrdU-stained cells
were also observed in regenerated collagen ﬁbers in G2-
PDRN, G3-MSC, and G4-MSC+PDRN, but only rarely in
G1-SAL (Figure 6C1–D4). Immunohistochemistry staining
revealed numerous VEGF-positive cells, and PECAM-1 pos-
itive microvascular densities were observed in G2-PDRN,
G3-MSC, and G4-MSC+PDRN (Figure 6E1–F4). In G4-
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MSC+PDRN, newly regenerated collagen type 1 ﬁbers, cell
proliferation, angiogenesis, walking distance, fast walking
time, and mean walking speed were greater than those in
the other three groups on histological examination and
motion analysis (Figures 7 and 8, Table 1).
4. Discussion
The major ﬁnding of this study is the superior therapeu-
tic eﬀect of coinjection with UCB-MSCs together with
PDRN, compared with UCB-MSCs alone when evaluated
functionally and histologically. PDRN has regenerative prop-
erties and stimulates wound healing by enhancing angiogen-
esis and production of VEGF through the adenosine A2
receptor stimulation [19]. To our knowledge, this is the ﬁrst
study to analyze the diﬀerence between stem cells and PDRN
or combination therapies for the regeneration of the rotator
cuﬀ tear. UCB-MSCs and PDRN can be produced in large
quantities while maintaining the same quality. It would be
ideal if the combination of PDRN and UCB-MSCs was syn-
ergistic in terms of their eﬀects or if PDRN was eﬀective
enough in the regeneration of RCTTs to replace expensive
stem cell-based therapy.
PDRN has been shown to improve the skin repair process
and enhance wound breaking strength in diabetic animals.
These eﬀects were associated with a marked increase in
A1 A2 A3 A4
B1 B2 B3 B4
Pretreatment
Posttreatment
Group 1: SAL Group 2: PDRN Group 3: MSC Group 4: MSC + PDRN
Figure 3: Gross morphological (A1–B4) ﬁndings of the subscapularis tendons in groups 1, 2, 3, and 4. (A1–A4) Pretreatment images. FTT is
observed in all four groups. (B1–B4) Posttreatment images. FTT is shown and no gross morphologic changes between pretreatment and four
weeks posttreatment in G1-SAL and G2-PDRN. There are signiﬁcant diﬀerences in gross morphologic changes between pretreatment and
four weeks posttreatment in G3-MSC and G4-MSC+PDRN. Normal saline (0.2mL; group 1: SAL), PDRN (0.2mL; group 2: PDRN),
MSC (0.2mL; group 3: MSC), and MSCs with PDRN (both 0.2mL; group 4: MSC+PDRN). MSC: human umbilical cord blood-derived
mesenchymal stem cell; PDRN: polydeoxyribonucleotide; FTT: full-thickness tendon tear.
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Figure 4: Gross morphology of tear site at 4 weeks postinjection.
FTT was observed in all eight rabbits in G1-SAL. In G2-PDRN,
a PTT was observed in three rabbits and FTT in ﬁve rabbits. In
G3-MSC, a PTT was observed in three rabbits, FTT in two
rabbits, and CH in three rabbits. In G4-MSC+PDRN, a PTT
was observed in ﬁve rabbits, FTT in one rabbit, and CH in two
rabbits. SAL (normal saline 0.2mL); PDRN (PDRN 0.2mL);
MSC (MSC 0.2mL); and MSC+PDRN (MSC 0.2mL with PDRN
0.2mL). PDRN: polydeoxyribonucleotide; MSC: human umbilical
cord blood-derived mesenchymal stem cell; FTT: full-thickness
tendon tear; PTT: partial-thickness tendon tear; CH: nearly
complete healing.
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Figure 5: Subscapularis tendon tear size at 4 weeks postinjection.
∗P < 0 05, one-way ANOVA, Tukey’s post hoc test between two
groups. SAL (group 1, normal saline 0.2mL); PDRN (group 2,
PDRN 0.2mL); MSC (group 3, MSC 0.2mL); and MSC
+PDRN (group 4, MSC 0.2mL with PDRN 0.2mL). PDRN:
polydeoxyribonucleotide; MSC: human umbilical cord blood-
derived mesenchymal stem cell.
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the expression of VEGF, a master regulator of angiogene-
sis that is impaired in diabetes-related wound disorders
[7]. We postulate that VEGF is a major growth factor that
accelerates the healing process by stimulating new vessel
formation in regions of poor circulation including full-
thickness tendon tear.
UCB-MSCs are an attractive stem cell source. Advan-
tages include noninvasive collection, superior tropism, and
diﬀerentiation potential [20]. In addition, UCB-MSCs are
less immunogenic; a recent study that used UCB-MSCs in
anterior cruciate ligament reconstruction in a rabbit model
showed no evidence of immune rejection [21]. The present
ﬁndings are consistent with this benign immune behavior.
PDRN contains a mixture of deoxyribonucleotide poly-
mers with chain lengths ranging from 50 to 2000 bp and is
a source of purine and pyrimidine deoxynucleosides/
A1 A2 A3 A4
B1 B2 B3 B4
MTS
COL-1
Group 1: SAL Group 2: PDRN Group 3: MSC Group 4: MSC + PDRN
C1 C2 C3 C4
D1 D2 D3 D4
E1 E2 E3 E4
F1 F2 F3 F4
BrdU
PCNA
VEGF
PECAM-1
Figure 6: Histological ﬁndings of the subscapularis tendons in group 1 (SAL), group 2 (PDRN), group 3 (MSC), and group 4 (MSC+PDRN).
(A1–A4) Newly regenerated tendons are shown in the blue-stained ﬁbers (black arrow; Masson’s trichrome stain; X200) in groups 2, 3, and 4.
Few regenerative collagen ﬁbers were seen in group 1. (B1–B4) Regenerated tendon ﬁbers (black arrow; X200) were stained with anti-type 1
collagen antibody in groups 2, 3, and 4. Few regenerated tendon ﬁbers were seen in group 1. (C1–D4) Numerous BrdU- and PCNA-stained
cells (black arrow, X400, X200) were observed in regenerated tendon ﬁbers in groups 2, 3, and 4. Few BrdU- and PCNA-stained cells were
observed in group 1. (E1-F4) Numerous VEGF-positive cells and PECAM-1 positive microvascular densities (black arrows, X200) were
observed in groups 2, 3, and 4. Few VEGF-positive cells and PECAM-1-positive microvascular densities were observed in group 1. MTS:
Masson’s trichrome stain; COL-1: collagen type 1; BrdU: 5-bromo-2′-deoxyuridine; PCNA: proliferating cell nuclear antigen; MSC:
human umbilical cord blood-derived mesenchymal stem cell; PDRN: polydeoxyribonucleotide; VEGF: vascular endothelial growth factor;
PECAM: platelet endothelial cell adhesion molecule.
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deoxyribonucleotides and bases [22]. PDRN has regenera-
tive properties and stimulates wound healing by enhancing
angiogenesis and production of VEGF through the adeno-
sine A2 receptor stimulation [19]. PDRN has no antigenic
properties since it consists of low-molecular weight DNA
fractions that can be deﬁned as deoxyribonucleotide linear
polymers [23]. Animal studies have demonstrated that
PDRN is not lethal and is nontoxic to the liver, lungs, brain,
skeletal muscle, and heart [24].
Another potential advantage of the combination of
PDRN and UCB-MSCs is that the eﬀect of exogenous
MSCs is not dose-dependent. If the eﬀect of exogenous
MSCs is not proportional to dose, it is better to combine
PDRN than to administer large amounts of MSCs to regener-
ate RCTT. A recent study in a porcine model of chronic myo-
cardial infarction found that cardiosphere-derived cells at
escalating doses led to equally enhanced preservation of car-
diac function and tissue remodeling without a dose-eﬃcacy
relationship [25]. Our previous (unpublished) ﬁndings agree
with this ﬁnding. We previously demonstrated that the injec-
tion of UCB-MSCs under US guidance has a regenerative
eﬀect for chronic full-thickness RCTTs. However, there were
no diﬀerences in these regenerative eﬀects between the high
and the low doses of the UCB-MSCs, which mean that the
beneﬁts of UCB-MSCs were not dose-dependent in our
rabbit model. Although further studies are needed, the fact
that the eﬀect of UCB-MSCs is not dose-dependent makes
the rational combination with PDRN more compelling.
In addition to comparing the eﬀect of UCB-MSC and
PDRN on FTRCTT, the current study has important features
in the method. The ﬁrst feature is the use of musculoskeletal
US for US-guided injection and evaluation of RCTT size after
injection. We tried to validate the eﬀect of only UCB-MSCs
or PDRN injection, not an adjuvant therapy for surgical
treatment in the FTRCTT model. The eﬀect of MSCs com-
bined with surgical repair has been reported in RCTT. How-
ever, combined with surgical repair, MSCs are an adjuvant
therapy, and the eﬀect of surgical repair overshadows their
exact role in regenerating torn tendons [26]. In this context,
musculoskeletal US can become a critical interventional tool
for regenerative injection therapies because US-guided injec-
tions allow the stem cells to be selectively administered to the
target area [18, 27]. Musculoskeletal US can also allow the
relatively accurate assessment of the extent of the tear during
the follow-up period before sacriﬁcing the rabbit. We con-
ﬁrmed full-thickness tendon tear by US 6 weeks after estab-
lishing the rotator cuﬀ tear. The four diﬀerent injectants
were separately introduced into the tear area under US guid-
ance. The size of the tendon tear was measured by US at pre-
injection and 4 weeks postinjection. The motion analysis of
the rabbits was also done to evaluate the improvement in
functional ability rather than the mechanical properties of a
regenerated tendon [18]. Motion analysis including walking
distance, fast walking time, and mean walking speed for 5
minutes was conducted at preinjection and 4 weeks postin-
jection. This analysis is not yet proven to be superior to the
mechanical testing that is frequently used in animal models
of the rotator cuﬀ tear [28–30]. However, motion analysis is
a potentially important tool to assess the therapeutic eﬀect
of the rotator cuﬀ tear, since functional tests have been dem-
onstrated to be an important tool to assess the eﬀectiveness of
treatments for FTRCTT in human studies [31].
Chronic RCTTs adversely aﬀect and hamper the surgical
repair of lesions [32]. In particular, massive FTRCTTs are
usually associated with myotendinous retraction, atrophy,
and fatty inﬁltration of the muscles, which are bad prognostic
factors for surgical outcomes. Thus, a “chronic” FTRCTT
model is needed to accurately assess the clinical utility of
MSCs in humans. For this study, we used a rabbit model of
a chronic traumatic RCTT after 6 weeks of trauma. Studies
in the rabbit supraspinatus muscle have shown fatty degener-
ation beginning as early as 4 weeks, with a peak at 6 weeks
and slow reversal by 12 weeks [33]. FTRCTT becomes irrep-
arable after approximately 6 weeks as the result of excessive
tendon retraction and muscle atrophy and stiﬀening [34].
Accordingly, we selected 6 weeks for the chronic injury
although we did not conﬁrm whether the “chronic” ﬁndings
were present in the tendon injuries [33–35].
There were signiﬁcant diﬀerences in gross morphologic
changes between preinjection and 4 weeks postinjection in
groups 3 and 4, but not in G1-SAL and G2-PDRN. The dif-
ference between the pairs of groups concerns the presence
or not of UCB-MSCs. G2-PDRN rabbits treated with
PDRN did not show the regeneration eﬀect. This proves
that the therapeutic eﬀect does not result from PDRN
alone. Although the initial focus of MSC treatment of muscu-
loskeletal injuries was based on their ability to diﬀerentiate
into several cell types, recent studies suggest that the beneﬁ-
cial eﬀect of stem cell-based therapy depends mainly on a
paracrine eﬀect [25, 36]. Paracrine signaling from MSCs
modulates many cellular responses including survival,
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Figure 7: Semiquantitative score of histological ﬁndings and
immunoreactivity of stain. The immunoreactivity of MTS and
anti-type 1 collagen antibody stain and proportion of BrdU-,
PCNA-, VEGF-, and PECAM-1-positive cells were scored as
detailed in Materials and Methods. ∗P < 0 05 one-way ANOVA,
Tukey's post hoc test among groups. SAL (group 1, normal saline
0.2mL); PDRN (group 2, PDRN 0.2mL); MSC (group 3, MSC
0.2mL); and MSC+PDRN (group 4, MSC 0.2mL with PDRN
0.2mL). MSC: human umbilical cord blood-derived mesenchymal
stem cell; PDRN: polydeoxyribonucleotide; VEGF: vascular
endothelial growth factor; PECAM: platelet endothelial cell
adhesion molecule.
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proliferation, migration, and gene expression [37, 38]. We
observed hypercellular ﬁbroblastic bundles composed of type
I collagens in the regenerated tendon 4 weeks after the injec-
tion of UCB-MSCs. The main cause of unsuccessful tendon
tear surgery is the formation of a ﬁbrovascular scar enriched
in type III collagens, which are mechanically weaker than
type I, the main component of the extracellular matrices in
tendons [39, 40]. The observation supports the idea that the
injection of USB-MSCs promotes the normal tendon healing
process in the repair of chronic RCTTs, even though USB-
MSCs did not presently diﬀerentiate into the target cell type.
The gross morphologic mean tendon tear size of each
group at 4 weeks postinjection were 13.08mm2 (G1-
SAL), 13.27mm2 (G2-PDRN), 3.36mm2 (G3-MSC), and
3.35mm2 (G4-MSC+PDRN). Since there were no signiﬁcant
diﬀerences in gross morphologic changes and tendon tear
size between G3-MSC and G4-MSC+PDRN, we were unable
to demonstrate whether the combined therapy with PDRN
and USB-MSCs was more eﬀective than USB-MSCs alone.
However, in G4-MSC+PDRN, newly regenerated collagen
type 1 ﬁbers, cell proliferation, angiogenesis, walking dis-
tance, fast walking time, and mean walking speed were
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Figure 8: Motion analysis of the rabbits at 4 weeks postinjection. In G4-MSC+PDRN, walking distance, fast walking time, and mean walking
speed are greater than those in the other three groups on motion analysis. ∗P < 0 05 one-way ANOVA, Tukey’s post hoc test among groups.
Group 1 (normal saline 0.2mL). Group 2 (PDRN 0.2mL). Group 3 (MSC 0.2mL). Group 4 (MSC 0.2mL with PDRN 0.2mL). MSC: human
umbilical cord blood-derived mesenchymal stem cell; PDRN: polydeoxyribonucleotide.
Table 1: Semiquantitative score of histological ﬁndings, immunoreactivity of stain, and motion analysis according to treatment groups at 4
weeks after injection.
Groups (injection regimens)
0.2mL NS
(G1-SAL)
0.2mL PDRN
(G2-PDRN)
0.2mL MSC
(G3-MSC)
0.2mL MSC+ 0.2mL PDRN
(G4-MSC+PDRN)
Histological score
MTS 0.0± 0.0∗ 0.9± 0.56∗ 2.2± 0.42∗ 3.0± 0.0∗
Anti-type collagen 1 0.2± 0.42∗ 1.1± 0.31∗ 2.1± 0.31∗ 3.0± 0.0∗
BrdU 0.88± 0.84∗ 1.54± 1.13∗ 2.05± 1.16∗ 2.54± 1.11∗
PCNA 1.27± 0.91∗ 2.10± 1.07∗ 2.70± 1.08∗ 3.11± 1.00∗
VEGF 1.27± 0.94∗ 2.00± 1.07∗ 2.64± 0.92∗ 3.18± 0.79∗
PECAM-1 1.68± 0.93∗ 2.22± 0.92∗ 2.86± 0.98∗ 3.36± 0.75∗
Motion analysis
Walking distance (cm) 4728.37± 137.27∗ 5416.62± 323.27∗ 6343.62± 213.57∗ 6932.37± 107.74∗
Fast walking time (%) 5.62± 1.42∗ 8.32± 0.34∗ 10.33± 2.48∗ 12.07± 1.77∗
Mean walking speed (cm/sec) 6.3± 0.57∗ 8.36± 0.39∗ 9.62± 1.78∗ 12.3± 1.13∗
Values are the mean ± SD. The immunoreactivity of MTS and anti-type 1 collagen antibody stain and proportion of BrdU-, PCNA-, VEGF-, and PECAM-1-
positive cells were scored as detailed in Materials and Methods. NS: normal saline; MSC: human umbilical cord blood-derived mesenchymal stem cell; PDRN:
polydeoxyribonucleotide; G1-SAL: 0.2 mL normal saline group; G2-PDRN: 0.2 mL PDRN; G3-MSC: 0.2 mL UCB-MSCs; G4-MSC + PDRN: 0.2 mL UCB-
MSCs with 0.2 ml PDRN; MTS: Masson’s trichrome stain; BrdU: bromodeoxyuridine; PCNA: proliferating cell nuclear antigen; VEGF: vascular endothelial
growth factor; PECAM-1: platelet endothelial cell adhesion molecule. P < 0 05 one-way ANOVA, Tukey’s post hoc test among groups.
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greater than those in the other three groups based on the
histological and motion analyses.
Therefore, when combined with USB-MSCs, PDRN
might have a synergic or additive eﬀect in the treatment
of RCTTs.
The exact mechanism of treatment for both USB-MSCs
and PDRN remains unknown. Paradoxically, the value of
the combined eﬀect of PDRN and MSCs is due to the limita-
tions of the MSC regenerative eﬀect. Accumulating evidence
suggests that the regenerative properties of exogenous MSCs
are mainly due to the paracrine mechanism because the
engrafted MSCs have poor diﬀerentiation and survival rates
[41–43]. This paracrine action may be accounted for, at least
in part, by microvesicles (MVs) released from MSCs, which
deliver proteins, bioactive lipids, and nucleic acids to injured
cells [44]. Although exogenous MSCs can be considered a
potential therapeutic tool and can contribute to tissue repair,
the extent of improvement of injured tissues has not been
correlated with cellular engraftment and diﬀerentiation of
MSCs to tissue cells. It is necessary to develop strategies to
obtain suﬃcient amounts of MVs. Since the paracrine eﬀect
of MSCs may not be proportional to the amount of MSCs
administered, other additional sources are needed to fully
provide the necessary protein (or its precursors), bioactive
factors, and nucleic acids [19, 22, 23]. It is assumed that the
PDRN can fulﬁll this role.
In the current study, 0.2mL of PDRN with or without
UCB-MSCs was injected into the right FTSSCT under US
guidance. This dose volume of PDRN was the same dose as
the stem cells. The optimal dose or route of administration
of PDRN required for regenerating the rotator cuﬀ was not
established. We estimated and used 0.2mL of PDRN because
rabbits weigh about 5% of the weight of a typical adult. One
study used 3mL in patients with chronic rotator cuﬀ tendi-
nopathy [9]. However, in studies on human subjects, PDRN
was injected directly into lesions to demonstrate therapeutic
eﬃcacy. A half vial of PDRN (1.5mL) was injected each week
for 3 weeks for the treatment of plantar fasciitis [8], and
5.625mg in 3mL of PDRN was injected at weekly intervals
for 3 weeks to treat chronic rotator cuﬀ tendinopathy [9].
To conﬁrm the regenerative eﬀect of the rotator cuﬀ tear of
the PDRN, it is necessary to clarify the optimal dose and
route of administration of PDRN.
There are some limitations in our study. First, we created
5mm diameter FTRCTTs near the insertion site on the left
subscapularis tendon by punch biopsy excision. After each
excision was made, each wound was immediately covered
with a round silicone tube to induce the chronic rotator cuﬀ
tear model. Each wound was closed using subcutaneous and
skin sutures. However, these tears were in the tendon body,
not exactly at the insertion site, which is not reestablished fol-
lowing surgical repair. This outcome is associated with high
recurrence rates [45]. Second, complete regeneration did
not occur. Current strategies for using stem cells to regener-
ate FTRCTTs can be combined with mechanical stimulation,
the topography of the extracellular matrix, growth and dif-
ferentiation factors, gene transfection, and coculture with
tendon tissues or cells. Future studies are needed that use
UCB-MSCs and/or PDRN with these factors [46]. Third,
the optimal dose of UCB-MSCs was determined based on
previous studies. However, as mentioned above, the dose of
PDRN was determined to be the same as UCB-MSCs for
comparison. However, this dose may not be the proper dose
of PDRN. Fourth, we did not perform the biomechanical test
of the regenerative tendon. Last, there would also have been
more “complete” rotator cuﬀ healing if outcomes were mea-
sured at 8 weeks or more instead of at 4 weeks.
5. Conclusion
There was no signiﬁcant diﬀerence in gross morphologic
change of the tendon tear between UCB-MSCs only and
the combination with PDRN injection in a rabbit model of
chronic traumatic FTRCTT. However, coinjection of UCB-
MSCs and PDRN was more eﬀective than the injection of
UCB-MSCs alone in histological and motion analyses. These
results of this study regarding the combination of UCB-
MSCs and PDRN warrant more investigations.
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